In January 2012, the CCSG-supported Genomics and DNA Analysis facilities consolidated their activities to form a comprehensive institutional genomics shared resource: the Sequencing and Microarray Facility (SMF). The mission of the SMF is to support genomics research at MD Anderson by providing investigators with access to state-of-the-art instrumentation and a high level of technical expertise in a centralized facility, thereby minimizing the duplication of expensive equipment while maintaining technical excellence. The SMF, located in a newly renovated 1600-square-foot laboratory space, provides a complete range of genomic services that includes project and technology consultation, RNA and DNA quality assessment and quantification, Sanger DNA sequencing, comprehensive lllumina next-generation sequencing services, gene resequencing, fluorescent fragment analysis, and TaqMan-based gene expression analysis. The SMF also provides complete DNA and RNA services for several microarray applications, including gene expression, single-nucleotide polymorphism, comparative genomic hybridization, chromatin immunoprecipitation microarrays, and microRNA profiling. MD Anderson has demonstrated its support and commitment to the SMF by providing more than $1.2 million in funding for the purchase of state-of-the-art instrumentation. Major equipment includes AB 3730 sequencers, lllumina Hiseq2000 sequencers, an AB 7900 Sequence Detection System, Affymetrix GeneChip systems, an Axon Genepix 4000B Scanner, a MAUI Hybridization System, and an lllumina BeadXpress and iScan. Since 2008, the SMF component facilities processed 785,638 samples for 399 Pis in 19 CCSG programs supporting 14 P01, 227 R01, and 14 SPORE grants. The total number of samples processed increased 39%, and the number of Pis using the SMF increased 32% over the previous grant period (3/1/02-2/28/07). Publications cited using the SMF have appeared in several high impact journals including Nat Genet, Lancet Oncol, Cell and Cancer Cell. Peer-reviewed Pis accounted for 96% of the samples processed. Funding for the new grant cycle is proposed to come from the CCSG (22%), user fees (77.8%) and institutional support (0.2%). Future plans include the expansion of the NGS service to include platforms for midscale and single-molecule sequencing. The SMF will continue to expand the range of NGS and validation services offered and develop methods that can successfully use MD Anderson's unique resource of archival tumor samples.

Public Health Relevance

The SMF is the primary sequencing and microarray facility of MD Anderson. The SMF provides essential genomic analysis services to support cancer center members in basic science, translational, and population based research programs. Addition of essential whole genome and whole transcriptome sequencing services has enabled researchers to do more exploratory biomarker experiments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759767
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$770,703
Indirect Cost
$289,216
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yang, Yi; Li, Chia-Wei; Chan, Li-Chuan et al. (2018) Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res 28:862-864
Hui, David; Hess, Kenneth; Dibaj, Seyedeh S et al. (2018) The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer 124:2246-2252
LeBleu, Valerie S; Kalluri, Raghu (2018) A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 11:
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Saltz, Joel; Gupta, Rajarsi; Hou, Le et al. (2018) Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23:181-193.e7
Dondossola, Eleonora; Alexander, Stephanie; Holzapfel, Boris M et al. (2018) Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10:
Yue, Jinbo; Shi, Qiuling; Xu, Ting et al. (2018) Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 27:1563-1570
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242

Showing the most recent 10 out of 12418 publications